Alpha-blockade : Monotherapy for hypertension and benign prostatic hyperplasia. / Kaplan, Steven A.; Kaplan, Norman M.In: Urology, Vol. 48, No. 4, 10.1996, p. 541-550.
Research output: Contribution to journal › Review article › peer-review
TY - JOUR
T1 - Alpha-blockade
T2 - Monotherapy for hypertension and benign prostatic hyperplasia
AU - Kaplan, Steven A.
AU - Kaplan, Norman M
N1 - Funding Information: 2, Boyle P: Epidemiology of benign prostatic hyperplasia: risk factors and concomitance with hypertension. Br J Clin Pract 48 (suppl 75): 18-22, 1994. 3. Holtgrewe HL, Ackermann R, Bay-Nielsen H, Coast B, Jonsson E, Levy E, Mazeman B, Standaert A, and Tajima P: The economics of BPH, in Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, and Murphy G (Eds) : Pro-ceedings of the Second International Consultation on Benign Prostatic Hyperplasia (BPH). Paris, June 27-30, 1993. 4. Garraway WM, Collins GN, and Lee RJ: High preva-lence of benign prostatic hypertrophy in the community. Lan-cet 338: 469-471, 1991. 5. Chute CG, Panser LA, Girman CJ, OesterlingJE, Guess HA, Jacobsen SJ, and Lieber MM: The prevalence of prosta-tism: a population-based survey of urinary symptoms. J Urol 150: 85-89, 1993. 6. Garraway WM, Russell EBAW, Lee RJ, Collins GN, McKelvie GB, Hehir M, Rogers ACN, and Simpson RJ: hnpact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract 43: 318-321, 1993. 7. Daneshgari F, and Crawford ED: Benign prostatic disease. Postgrad Med 93: 82-84, 1993. 8. Sever P, Beevers G, Bulpitt C, Lever A, Ramsay L, Reid 3, and Swales j: Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 306: 983-987, 1993. 9. Guidelines subcommittee: 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. J Hypertens 11: 905-918, 1993. 10. Joint National Committee: 1993 Report of theJNC on detection, evaluation and treatment of high blood pressure. Arch intern Med 153: 154-183, 1993. 11, McConnellJD, Barry MJ, Bruskewitz RC, Bneschen AF, Denton SE, Hohgrewe HL, Lange JL, McClennan BL, Mebust WK, Reilly NJ, et al: Benign prostatic hyperplasia: diagnosis and treatment. Clinical Practice Guideline, Number 8. AHCPR Publication No. 94-0582. Rockville, Md: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, February 1994. 12. Cockett AT, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, and Murphy G: Recommendations of the International Consensus Committee concerning 1. prostate syrup-tmn score (I-PSS) and quality of life assessment 2. diagnostic work up of patients presenting with symptoms suggestive of prostatism 3. standardization of the evaluation of treatment modalities 4. BPH treatment recommendations, in Proceedings from the 2nd International Consuhation on Benign Prostatic Hyperplasia (BPH). Scientific Communication International, Jersey, June 1993, pp 553-564. 13. Isaccs JT, and Coffey DS: Etiology and disease process of benign prostatic hyperplasia. Prostate 2: 33-50, 1989. 14. Kaplan NM: Clinical Hypertension, 6th ed. Bahimore, Williams & Wilkins, 1994. 15. Berry SJ, Coffey DS, Walsh PC, and Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 132: 474-479, 1984. 16. Julius S, Pascaul AV, and London R: Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation 44: 413-418, 197I. 17. Yamada Y, Miyajima E, Tochikubo O, Matsukawa T, and lshii M: Age-related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension 13: 870-877, 1989. 18. Ng AV, Callister R, Johnson DG, and Seals DR. Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. Hypertension 21: 498-503, 1993. 19. Chapple CR, Aubry ML, James S, Greengrass PM, Burnstock G, Turner-Warwick RT, Milroy EJG, and Davey MJ: Characterization of human prostatic adrenoceptors using pharmacology receptor binding and localization. Br J Urol 63: 487-496, 1989. 20. Shapiro E, Hartanto V, and Lepor H: The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 21: 297-307, 1992. 21. Ford APDW, Williams TJ, Blue DR, and Clarke DE: Alphat-adrenoceptor classification: sharpening Occam's razor. Trends Pharrnacol Sci 15: 167-170, 1994. 22. Forray C, BardJA, WetzelJM, Chin G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha lc subtype. Mol Pharmacol 45: 703-708, 1994. 23. Marshall I, Burt RP, Andersson PO, et al: Human alc-adrenoceptor: functional characterization in prostate. Br J Pharmacol 107: 327P, 1992. 24. Jonler M, Riehmann M, and Bruskewitz RC: Benign prostatic hyperplasia. Current pharmacological treatment. Drugs 47: 66-81, 1994. 25. Pickering TG, Levenstein M, and Walmsley P: Night-time dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT study. AmJ Hy-pertens 7: 844-847, 1994. 26. PanzaJA, Epstein SE, and Quyyami AA: Circadian variation in vascular tone and its relation to a-sympathetic vasoconstrictor activity. N EnglJ Med 325: 986-990, 1991. 27. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Gran-dits GA, Elmer PJ, CutlerJA, FlackJM, SchoenbergerJA, Mac-Donald R, et al for the Treatment of Mild Hypertension Group: Treatment of Mild Hypertension Study. Final results. JAMA 270: 713-724, 1993. 28. Hayduk K, and Schneider HT: Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin. Am J Cardiol 58: 95G-98G, 1987. 29. Cohen J: Long-term efficacy and safety of terazosin. J Clin Pharmacol 33: 272-278, 1993. 30. Talseth T, Westlie L, and Daae L: Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up. Am HeartJ 121: 280-285, 1991. 31. Langdon CG, and Packard RS: Doxazosin in hypertension: results of a general practice study in 4809 patients. BrJ Clin Pract 48: 293-298, 1994. 32. Kasiske BL, MaJZ, Kalil RSN, and Louis TA: Effects of antihypertensive therapy on serum lipids. Ann Intern Med 122: 133-141, 1995. 33. Kaplan NM: The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149: 1514-1520, 1989. 34. Feher MD: Doxazosin therapy in the treatment of diabetic hypertension. Am HeartJ 121: 1294-1301, 1991. 35. Ames RP: The influence of non-beta-blocking drugs on the lipid profile. Are diuretics outclassed as initial therapy for hypertension? Am HeartJ 114: 998-1006, 1987. 36. Kaplan NM: Effects of antihypertensive therapy on insulin resistance. Hypertension 19 (suppl I): 116-118, 1992. 37. Lithell H: Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 14: 203-209, 1991. 38. Giordano M, and Matsuda M: Effects of captopril (CAP), nifedipine (NIF) and doxazosin (DOX) on insulin sensitivity in non-insulin dependent diabetic (NIDD) hypertensive patients. Diabetes 43: A79, 1994. 39. Chapple CR, Stott M, Abrams PH, Christmas TJ, and Milroy EJG: A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia. BrJ Urol 70: 285-294, 1992. 40. Lepor H, Anerbach S, Puras-Baez A, Narayan P, Solo-way M, Lowe F, Moon T, Leifer G, and Madsen P: A randomized, placebo-controlled muhicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 148: 1467-1474, 1992. 41. Christensen MM, Holme JB, Rasmussen PC, Jacobsen F, Nielsen J, NorgaardJP, Olesen S, Noer I, Wolf H, and Hus-ted 5E: Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. Scand J Urol Nephrol 27: 39-44, 1993. 42. GillenwaterJY, Corm RL, Chrysant SG, Roy J, Gaffney M, Ice K, and Dias N: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 154: 110-115, 1995. 43. Lepor H: Long-term efficacy and safety of doxazosin for the treatment of benign prostatic hyperplasia (abstract 180). J Urol 153: 273A, 1995, 44. Lepor H: Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 45: 406-413, 1995. 45. Bendix Holme J, Christensen MM, Rasmussen PC, Jacobsen F, Nielsen J, Norgaard JP, Olesen S, Noer I, Wolf H, and Elkjaer Husted S: 29 week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. Scand J Urol Nephro128: 77-82, 1994. 46. Wilde MI, Fitton A, and McTavish D: Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs 45: 410-429, 1993. 47. Buzelin JM, Hebert M, Blondin P, and PRAZALF Group: Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. Br J Urol 72: 922-927, 1993. 48. Teillac P, Delauch-Cavallier MC, Attali P, and DUALF Group: Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. BrJ Uro170: 58-64, 1992. 49, Lepor H: Clinical evaluation of tamsulosin, a prostate selective alpha le antagonist (abstract 182). J Urol 153: 274A, 1995. 50. Abrams P, Schuhnan CC, and Vaage S: The efficacy and safety of .4 nag tamsulosin once daily in symptomatic BPH (abstract 183). J Urol 153: 274.4., 1995. 51. Kaplan SA, Goluboff ET, Olsson CA, Deverka PA, and ChmM JJ: Effect of demographic factors, urinary peak [low rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. Urology 45: 398-405, 1995. 52. Jardin A, Kirby RS, Christensen MM,Janknegt RA, Gil-lenwater J, and Fawzy A: Doxazosin is equally well tolerated by older and younger normotensive men (abstract 179). J Urol I53: 273A, 1995. 53. Hosmane BS, Maurath CJ, Jordan DC, and Laddu A: Effect of age and dose on the it~cidenee of adverse events in the treatment of hypertension i~ patients receiving terazosin. J Clin Pharmaeol 32: 434-443, 1.992. 54. Janknegt RA, and Chapple CR: Efficacy and safety of the alpha-I blocker doxazosin tn the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Eur Uro124:31.9-326, 1.993. 55. Kirby RS: Profile of doxazosin in the hypertensive man with benign prostatic hyperp]asia. BrJ Clin Pract 74: 23-28, 1994. 56. Kirby RS: Doxazosin in benign prostatic hyperplasia (BPH) : differential effects on the blood pressure of normoten-sire and hypertensive men, Urology 46: 182-186, 1995. 57. Kaplan SA, Meade-D'Alisera 17, Quinones S, and Soldo KA: Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia: a study of safety and efficacy. Urology 46: 51.2-517, 1995. 58. Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, and Dias N: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a nmlticenter study. J Urol 154: 105-109, 1995. Funding Information: The drugs of most interest are the selective alphal-adrenoceptor antagonists. These drugs have been recommended as first-line antihypertensive agents by the British Hypertension Society, a the World Health Organization/International Society of Hypertension, 9 and the Joint National Committee (1993) on the Detection, Evaluation, and Treatment of Hypertension, lO among other organizations, and they have also been recommended for the treatment of BPH by the Agency for Health Care Policy and Research n and the International Consultation on Benign Prostatic Hyperplasia. t2 This review will consider the epidemiologic and etiologic links between BPH and hypertension and will also discuss the rationale for selective alphal-adrenoceptor blockade in treating both disorders. It will review the published information on the efficacy and safety of the major drugs in the group: doxazosin, prazosin, terazosin, alfuzosin, and tamsulosin.
PY - 1996/10
Y1 - 1996/10
UR - http://www.scopus.com/inward/record.url?scp=0030273035&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030273035&partnerID=8YFLogxK
U2 - 10.1016/S0090-4295(96)00242-7
DO - 10.1016/S0090-4295(96)00242-7
M3 - Review article
C2 - 8886058
AN - SCOPUS:0030273035
VL - 48
SP - 541
EP - 550
JO - Urology
JF - Urology
SN - 0090-4295
IS - 4